# Clinical Trials Data BRAF - Document 20

# Interest of the 18F-DOPA-PET Imaging in Metastatic Melanoma Treated With B-RAF Inhibitors: a Pilot Study

## Clinical Trial: https://clinicaltrials.gov/study/NCT02038348

"eligibilityCriteria": "Inclusion Criteria:\n\n\* B-RAF mutated metastatic melanoma.\n\* Reference imaging \\<1 month inclduing a whole body CT and 18F-FDG.\n\* At least one metastatic lesion at least with a diameter\\> 10 mm on CT.\n\* To which the staff has proposed, a B-RAF inhibitor in first-line treatment\n\* Signed informed consent.\n\nExclusion Criteria:\n\n\* Minor subject.\n\* Subject diabetic.\n\* Women of childbearing potential without effective contraception, with positive pregnancy test.\n\* Other known active cancer.\n\* No affiliation to a social security (beneficiary or assignee).",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
]

Question:  
Based on the following clinical trial information, would a patient with a BRAF gene mutation be eligible for the clinical trial?

Answer:  
Based on the eligibility criteria provided for the clinical trial, a patient with a BRAF gene mutation would indeed be eligible for the trial, given they meet the inclusion and none of the exclusion criteria.   
  
The key inclusion criterion relevant to your question is "B-RAF mutated metastatic melanoma," which directly addresses the requirement for the BRAF gene mutation. However, the patient must also meet other criteria, such as having a reference imaging status, a metastatic lesion of the required size, and the proposed treatment of a BRAF inhibitor. Additionally, the patient must provide informed consent and not meet any of the exclusion criteria (e.g., being a minor, having diabetes, being a female without effective contraception if of childbearing potential, having another active cancer, or lacking social security affiliation).